Irreversibly-inactivated pepsinogen fragments for modulating immune function

• US 8,309,072 B2
• Filed: 06/18/2009
• Issued: 11/13/2012
• Est. Priority Date: 11/12/2004
• Status: Active Grant

• Current Assignee: The Zhabilov Trust
• Original Assignee: The Zhabilov Trust
• Inventors: Zhabilov, Harry H.
• Primary Examiner(s): LI, BAO Q
• Application Number:
  US12/487,637
• Publication Number:
  US 20090285776A1
• Time in Patent Office: 1,244 Days
• Field of Search: None
• US Class Current: 424/93.1
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 38/2013 IL-2
• CPC Class Codes: A61K 38/488 Aspartic endopeptidases (3.4.23), e.g. pepsin, chymosin, renin, cathepsin E
• CPC Class Codes: A61K 39/39 characterised by the immunostimulating additives, e.g. chemical adjuvants

Abstract

Isolated anti-cancer peptides are disclosed which are characterized by the amino acid sequences TLTSGGGAIALPPSMAAPPLGPVAPLTGAIHAPTXG (SEQ ID NO: 1); TLSTATGGAIPPVAAMPPGLVAPTHGPAIHP (SEQ ID NO: 2); CCATSGPCGAVMILTPHLTA (SEQ ID NO: 5); MTLTTGSGAIAPAMPPGLPPHTGAIHAPM (SEQ ID NO: 4); and NXVPVSVEGYXQITLDSITX (SEQ ID NO: 3) and a significant in vitro binding affinity for gp96. The peptides exhibit anti-tumor, anti-cancer activity in vivo. Also disclosed is an isolated antiviral peptide characterized by the amino acid sequence GDEPLENYLDTEYF (SEQ ID NO: 6) and a significant in vitro binding affinity for HIV-1 gp 120 and gp 41, and human CD4 cells. The peptide exhibits anti-retroviral activity in vivo, particularly anti-HIV-1 activity.

Claims

1. An method of modulating immune activity comprising administering to a patient an effective amount of a composition comprising an inactivated pepsin fragment (IPF).

2. The method of claim 1, wherein the inactivated pepsin fragment (IPF) comprising the amino acid sequence of SEQ ID:

NO. 1.

3. The method of claim 2, wherein modulating immune function comprises conferring immunity against malignant human cancer cells, and comprising the step of administering to a patient a composition comprising SEQ ID:

NO. 1 combined with IL-2.